These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1670 related articles for article (PubMed ID: 31959728)

  • 1. Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in
    Peng XX; Yu R; Wu X; Wu SY; Pi C; Chen ZH; Zhang XC; Gao CY; Shao YW; Liu L; Wu YL; Zhou Q
    J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum exosomal microRNAs as predictive markers for EGFR mutations in non-small-cell lung cancer.
    Xia J; Luo M; Dai L; Wang L; Wang L; Zhu J
    J Clin Lab Anal; 2021 May; 35(5):e23743. PubMed ID: 33682961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer.
    Shimada Y; Matsubayashi J; Kudo Y; Maehara S; Takeuchi S; Hagiwara M; Kakihana M; Ohira T; Nagao T; Ikeda N
    Sci Rep; 2021 Apr; 11(1):7830. PubMed ID: 33837261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid exosomal microRNAs as biomarkers for diagnosing or monitoring the progression of non-small cell lung cancer with leptomeningeal metastases.
    Li H; Xia M; Zheng S; Lin Y; Yu T; Xie Y; Shen Y; Liu X; Qian X; Yin Z
    Biotechnol Genet Eng Rev; 2024 Apr; 40(1):359-380. PubMed ID: 36852928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer.
    Chen X; Xu Y; Liao X; Liao R; Zhang L; Niu K; Li T; Li D; Chen Z; Duan Y; Sun J
    Tumour Biol; 2016 Sep; 37(9):11927-11936. PubMed ID: 27075472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
    Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
    Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum exosomal miR-16-5p functions as a tumor inhibitor and a new biomarker for PD-L1 inhibitor-dependent immunotherapy in lung adenocarcinoma by regulating PD-L1 expression.
    Chen HL; Luo YP; Lin MW; Peng XX; Liu ML; Wang YC; Li SJ; Yang DH; Yang ZX
    Cancer Med; 2022 Jul; 11(13):2627-2643. PubMed ID: 35347894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer.
    Liu Q; Yu Z; Yuan S; Xie W; Li C; Hu Z; Xiang Y; Wu N; Wu L; Bai L; Li Y
    Oncotarget; 2017 Feb; 8(8):13048-13058. PubMed ID: 28055956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
    Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
    Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with
    Oya Y; Kuroda H; Nakada T; Takahashi Y; Sakakura N; Hida T
    Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32283823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The expression of circulating miR-504 in plasma is associated with EGFR mutation status in non-small-cell lung carcinoma patients.
    Szpechcinski A; Florczuk M; Duk K; Zdral A; Rudzinski S; Bryl M; Czyzewicz G; Rudzinski P; Kupis W; Wojda E; Giedronowicz D; Langfort R; Barinow-Wojewodzki A; Orlowski T; Chorostowska-Wynimko J
    Cell Mol Life Sci; 2019 Sep; 76(18):3641-3656. PubMed ID: 30953094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exosomal microRNAs as potential biomarkers for osimertinib resistance of non-small cell lung cancer patients.
    Janpipatkul K; Trachu N; Watcharenwong P; Panvongsa W; Worakitchanon W; Metheetrairut C; Oranratnachai S; Reungwetwattana T; Chairoungdua A
    Cancer Biomark; 2021; 31(3):281-294. PubMed ID: 33896827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of circulating exosomal miR-17-5p serves as a novel non-invasive diagnostic marker for non-small cell lung cancer patients.
    Zhang Y; Zhang Y; Yin Y; Li S
    Pathol Res Pract; 2019 Aug; 215(8):152466. PubMed ID: 31146974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
    Sakai H; Takeda M; Sakai K; Nakamura Y; Ito A; Hayashi H; Tanaka K; Nishio K; Nakagawa K
    Lung Cancer; 2019 Jan; 127():59-65. PubMed ID: 30642552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating microRNAs as novel biomarkers of ALK-positive nonsmall cell lung cancer and predictors of response to crizotinib therapy.
    Li LL; Qu LL; Fu HJ; Zheng XF; Tang CH; Li XY; Chen J; Wang WX; Yang SX; Wang L; Zhao GH; Lv PP; Zhang M; Lei YY; Qin HF; Wang H; Gao HJ; Liu XQ
    Oncotarget; 2017 Jul; 8(28):45399-45414. PubMed ID: 28514730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.
    Zhang B; Zeng J; Zhang H; Zhu S; Wang H; He J; Yang L; Zhou N; Zu L; Xu X; Song Z; Xu S
    Front Immunol; 2022; 13():974581. PubMed ID: 36159860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.
    Gainor JF; Shaw AT; Sequist LV; Fu X; Azzoli CG; Piotrowska Z; Huynh TG; Zhao L; Fulton L; Schultz KR; Howe E; Farago AF; Sullivan RJ; Stone JR; Digumarthy S; Moran T; Hata AN; Yagi Y; Yeap BY; Engelman JA; Mino-Kenudson M
    Clin Cancer Res; 2016 Sep; 22(18):4585-93. PubMed ID: 27225694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Role of Circulating Exosomal miR-425-3p for the Response of NSCLC to Platinum-Based Chemotherapy.
    Yuwen D; Ma Y; Wang D; Gao J; Li X; Xue W; Fan M; Xu Q; Shen Y; Shu Y
    Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):163-173. PubMed ID: 30228154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Tumor-Derived Exosomal miRNA as Potential Diagnostic Biomarkers for Early-Stage Non-Small Cell Lung Cancer Using Next-Generation Sequencing.
    Jin X; Chen Y; Chen H; Fei S; Chen D; Cai X; Liu L; Lin B; Su H; Zhao L; Su M; Pan H; Shen L; Xie D; Xie C
    Clin Cancer Res; 2017 Sep; 23(17):5311-5319. PubMed ID: 28606918
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 84.